The partners in a just-announced life sciences research collaboration between Eli Lilly and Co. (NYSE: LLY) and Purdue University say the deal could have implications that extend far beyond the two institutions. The five year, $52 million partnership is designed to expand Lilly’s efforts to get medicines to market more efficiently, says Lilly Research Labs Chief Operating Officer Andrew Dahlem, who says talent is key to making it happen.

{{ articles_remaining }}
Free {{ article_text }} Remaining
{{ articles_remaining }}
Free {{ article_text }} Remaining Article limit resets on
{{ count_down }}